Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity

Inclusion Criteria

• •Male or female, age 18- less than (\<) 50 years at the time of signing informed consent.
• •Diagnosed with type 2 diabetes mellitus less than or equal to (\<=) 365 days from the day of screening.
• •Glycated haemoglobin (HbA1c) of 7.0-9.5 percentage (%) (53-80 millimoles per milliliter \[mmol/mol\]) (both inclusive).
• •Body mass index (BMI) greater than or equal to (\>=) 30.0 kilograms per meter square (kg/m\^2).
• •Treatment naïve to any antidiabetic drug(s). However, for a subset of participants (≤25%) any metformin dose or formulations administered is allowed.
• •Renal impairment measured as estimated glomerular filtration rate (eGFR) value of less than (\<) 60 milliliter per minute per 1.73 meter square (1.7mL/min/1.73 m\^2) at screening.
• •Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to day of screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
• •C-peptide less than (\<)1.5 nanograms per milliliter (ng/mL) at screening.
• •Positive insulinoma associated-protein 2 (IA-2) antibodies or anti-glutamic acid decarboxylase (anti-GAD) antibodies.
• •History of major surgical procedures involving the stomach or small intestine potentially affecting absorption of drugs and/or nutrients.
• •Presence of clinically significant gastrointestinal disorders potentially affecting absorption of drugs and/or nutrients, as judged by the investigator.